New PhD opportunity in health economics and genomics

I’m pleased to announce that we are offering a DPhil (PhD) position here at the Health Economics Research Centre in the area of health economics and genomics. The proposed start date is October 2017 and the full title is “Linking genomic and clinical data in health economic evaluations: identifying challenges and exploring potential solutions“.

The aim of this DPhil project is to comprehensively investigate the challenges and opportunities in this area using data from the 100,000 Genomes Project, with an emphasis on rare diseases.

The deadline for applications is 1200 noon UK time on Friday 6th January 2017.

If anybody has any questions about this project then please don’t hesitate to get in touch by email ( Please also share the details of this project with anybody who you think might be interested.

Full details of this project are available here.


What are people willing to pay for whole genome sequencing information?

Given the wide variety of health and non-health outcomes associated with genomic tests, it is perhaps particularly important that the preferences of key stakeholders are considered within the health technology assessment process for these interventions. Indeed, in a paper published last year, Rogowski et al. highlight the importance of ‘preference-based personalization’ in this context. To date, few studies have generated data on preferences for genomic tests. However, a recent publication in Genetics in Medicine by Deborah Marshall and colleagues has attempted to address this gap in the literature.

Continue reading


Hello. Chances are you’re a health economist, although you might also be a researcher in a different field of healthcare. You might even be a scientist (apologies in advance for any bad science that might follow). Whoever you are, you’re very welcome. The aim of this introductory post is to tell you what you should expect from this blog. Hopefully you’ll be sufficiently intrigued to return, read some more articles and contribute to the growing debate surrounding the application of standard health economic methods in the field of genomics.

This blog is going to assume that you know a little bit about genomics. Specifically, this blog is going to assume that you have at least read the “What are genomic technologies?” section of this blog, a short introduction for a layperson who already has a little bit of science knowledge. Of course, many of you will have a greater knowledge of genetics and genomics than this simple introduction, but this blog is intended to be broadly accessible to stimulate wide debate, so the aim is to keep the genomics jargon to a minimum. This blog is also going to assume that the average reader has some basic knowledge about health economics. Those who don’t could do a lot worse than frequent the excellent “Academic Health Economists’ Blog”.

Continue reading